Compare HCA Health Inc (HCA) vs Norwegian Cruise Line Holdings Ltd (NCLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HCA Health Inc vs Norwegian Cruise Line Holdings Ltd — how do they compare? HCA Health Inc trades at $445.72 (market cap $96.35B), while Norwegian Cruise Line Holdings Ltd trades at $15.58 (market cap $7.11B). The key difference: HCA Health Inc is far larger — about 13.6× Norwegian Cruise Line Holdings Ltd's market cap, and HCA Health Inc pays a 0.7% dividend while Norwegian Cruise Line Holdings Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold HCA Health Inc for 76 Days and Norwegian Cruise Line Holdings Ltd for 68 Days on average.
| HCA | NCLH | |
|---|---|---|
Market Cap | $96.35B | $7.11B |
Volume | 1,079,453 | 22,683,268 |
Sector | Health | Consumer Cyclical |
52-Week High | $545.13 | $25.02 |
52-Week Low | $361.32 | $14.12 |
Typical Hold Time | 76 Days | 68 Days |
Enterprise Value | $146.88B | $21.93B |
Dividend Yield | 0.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HCA Healthcare (HCA) trades at $439.17, up 1.61% today, with a bullish technical signal and strong fundamental performance. Revenue grew to $75.6 billion in 2025, with net income reaching $6.78 billion, and the company has beaten EPS estimates for three consecutive quarters. Recent news includes an upcoming Q3 2026 earnings call and the completion of the College of Health Care Professions acquisition, highlighting operational expansion.
The outlook remains positive with a consensus price target of $461.12, though risks include ongoing legal investigations and high debt levels. Earnings growth and cost controls support upside potential, but investors should monitor regulatory developments and payer-mix pressures that could impact margins.
Norwegian Cruise Line Holdings (NCLH) trades at $15.05, down 2.97% on the day, with a neutral technical signal and bearish moving average trend. The company reported strong earnings beats in recent quarters, with Q3 2026 expected to exceed guidance at $0.914 EPS. Fundamentals show robust revenue growth to $9.83B in 2025, though net income margin compressed to 4.3%. Recent news highlights yield pressure and a $950M senior notes offering.
NCLH presents a mixed outlook: valuation appears attractive with a P/E of 9.39 and analyst consensus target of $20.86, implying upside. However, high debt levels, net yield pressures, and volatile cash flows pose risks. The stock offers potential for recovery if operational improvements and pricing strategies stabilize profitability through 2027.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →
